Inhibition of the transcriptional function of p53 by EWS-Fli1 chimeric protein in Ewing Family Tumors

Cancer Letters

Volumn 294, Issue 1, 2010, Pages 57-65

  Li, Yan ^a,b   Tanaka, Kazuhiro ^a   Fan, Xueli ^a   Nakatani, Fumihiko ^a   Li, Xu ^a,b   Nakamura, Tomoyuki ^a   Takasaki, Minoru ^a   Yamamoto, Shunsaku ^a   Iwamoto, Yukihide ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Ewing Family Tumors; Fusion gene; P53

Indexed keywords

HYBRID PROTEIN; MESSENGER RNA; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; RNA BINDING PROTEIN EWS; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FLI 1;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA DAMAGE; EWING SARCOMA; GENE DELETION; GENE EXPRESSION REGULATION; GENE INTERACTION; GENE LOCATION; GENE REPRESSION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION REGULATION;

3T3 CELLS; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 22; DNA PRIMERS; FIBROBLASTS; GENES, REPORTER; HUMANS; LUCIFERASES; MICE; ONCOGENE PROTEINS, FUSION; OSTEOSARCOMA; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEIN C-FLI-1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SARCOMA, EWING'S; TRANSCRIPTION, GENETIC; TRANSFECTION; TRANSLOCATION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77953028157     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.01.022     Document Type: Article

References (41)

1. Turc-Carel C., Philip I., Berger M.P., Philip T., Lenoir G.M. Chromosome study of Ewing's sarcoma (ES) cell lines. Consistency of a reciprocal translocation t(11;22)(q24;q12). Cancer Genet. Cytogenet. 1984, 12:1-19.
2. Janknecht R. EWS-ETS oncoproteins: the linchpins of Ewing tumors. Gene 2005, 363:1-14.
3. Tanaka K., Iwakuma T., Harimaya K., Sato H., Iwamoto Y. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J. Clin. Invest. 1997, 99:239-247.
4. Riggi N., Cironi L., Provero P., Suva M.L., Kaloulis K., Garcia-Echeverria C., Hoffmann F., Trumpp A., Stamenkovic I. Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res. 2005, 65:11459-11468.
5. Riggi N., Suva M.L., Suva D., Cironi L., Provero P., Tercier S., Joseph J.M., Stehle J.C., Baumer K., Kindler V., Stamenkovic I. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res. 2008, 68:2176-2185.
6. Tirode F., Laud-Duval K., Prieur A., Delorme B., Charbord P., Delattre O. Mesenchymal stem cell features of Ewing tumors. Cancer Cell 2007, 11:421-429.
7. Matsumoto Y., Tanaka K., Nakatani F., Matsunobu T., Matsuda S., Iwamoto Y. Downregulation and forced expression of EWS-Fli1 fusion gene results in changes in the expression of G(1)regulatory genes. Brit. J. Cancer 2001, 84:768-775.
8. Nakatani F., Tanaka K., Sakimura R., Matsumoto Y., Matsunobu T., Li X., Hanada M., Okada T., Iwamoto Y. Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein. J. Biol. Chem. 2003, 278:15105-15115.
9. Matsunobu T., Tanaka K., Matsumoto Y., Nakatani F., Sakimura R., Hanada M., Li X., Oda Y., Naruse I., Hoshino H., Tsuneyoshi M., Miura H., Iwamoto Y. The prognostic and therapeutic relevance of p27kip1 in Ewing's family tumors. Clin. Cancer Res. 2004, 10:1003-1012.
10. Dauphinot L., De Oliveira C., Melot T., Sevenet N., Thomas V., Weissman B.E., Delattre O. Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2and c-Myc expression. Oncogene 2001, 20:3258-3265.
11. Li X., Tanaka K., Nakatani F., Matsunobu T., Sakimura R., Hanada M., Okada T., Nakamura T., Iwamoto Y. Transactivation of cyclin E gene by EWS-Fli1 and antitumor effects of cyclin dependent kinase inhibitor on Ewing's family tumor cells. Int. J. Cancer 2005, 116:385-394.
12. Iwamoto Y. Diagnosis and treatment of Ewing's sarcoma. Jpn. J. Clin. Oncol. 2007, 37:79-89.
13. Deneen B., Denny C.T. Loss of p16 pathways stabilizes EWS/FLI1 expression and complements EWS/FLI1 mediated transformation. Oncogene 2001, 20:6731-6741.
14. Lessnick S.L., Dacwag C.S., Golub T.R. The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. Cancer Cell 2002, 1:393-401.
15. Hamelin R., Zucman J., Melot T., Delattre O., Thomas G. P53 mutations in human tumors with chimeric EWS/FLI-1 genes. Int. J. Cancer. 1994, 57:336-340.
16. Komuro H., Hayashi Y., Kawamura M., Hayashi K., Kaneko Y., Kamoshita S., Hanada R., Yamamoto K., Hongo T., Yamada M., et al. Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas. Cancer Res. 1993, 53:5284-5288.
17. Maki K., Mitani K., Yamagata T., Kurokawa M., Kanda Y., Yazaki Y., Hirai H. Transcriptional inhibition of p53 by the MLL/MEN chimeric protein found in myeloid leukemia. Blood 1999, 93:3216-3224.
18. Salomoni P., Pandolfi P.P. The role of PML in tumor suppression. Cell 2002, 108:165-170.
19. Wiederschain D., Kawai H., Gu J., Shilatifard A., Yuan Z.M. Molecular basis of p53 functional inactivation by the leukemic protein MLL-ELL. Mol. Cell Biol. 2003, 23:4230-4246.
20. Matsunobu T., Tanaka K., Nakamura T., Nakatani F., Sakimura R., Hanada M., Li X., Okada T., Oda Y., Tsuneyoshi M., Iwamoto Y. The possible role of EWS-Fli1 in evasion of senescence in Ewing family tumors. Cancer Res. 2006, 66:803-811.
21. Li Y., Tanaka K., Li X., Okada T., Nakamura T., Takasaki M., Yamamoto S., Oda Y., Tsuneyoshi M., Iwamoto Y. Cyclin-dependent kinase inhibitor, flavopiridol, induces apoptosis and inhibits tumor growth in drug-resistant osteosarcoma and Ewing's family tumor cells. Int. J. Cancer 2007, 121:1212-1218.
22. Petermann R., Mossier B.M., Aryee D.N., Khazak V., Golemis E.A., Kovar H. Oncogenic EWS-Fli1 interacts with hsRPB7, a subunit of human RNA polymerase II. Oncogene 1998, 17:603-610.
23. Spahn L., Petermann R., Siligan C., Schmid J.A., Aryee D.N., Kovar H. Interaction of the EWS NH2 terminus with BARD1 links the Ewing's sarcoma gene to a common tumor suppressor pathway. Cancer Res. 2002, 62:4583-4587.
24. Bailly R.A., Bosselut R., Zucman J., Cormier F., Delattre O., Roussel M., Thomas G., Ghysdael J. DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma. Mol. Cell Biol. 1994, 14:3230-3241.
25. Tirado O.M., Mateo-Lozano S., Villar J., Dettin L.E., Llort A., Gallego S., Ban J., Kovar H., Notario V. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells. Cancer Res. 2006, 66:9937-9947.
26. Nishimori H., Sasaki Y., Yoshida K., Irifune H., Zembutsu H., Tanaka T., Aoyama T., Hosaka T., Kawaguchi S., Wada T., Hata J., Toguchida J., Nakamura Y., Tokino T. The Id2 gene is a novel target of transcriptional activation by EWS-ETS fusion proteins in Ewing family tumors. Oncogene 2002, 21:8302-8309.
27. Hahm K.B., Cho K., Lee C., Im Y.H., Chang J., Choi S.G., Sorensen P.H., Thiele C.J., Kim S.J. Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein. Nat. Genet. 1999, 23:222-227.
28. Jaishankar S., Zhang J., Roussel M.F., Baker S.J. Transforming activity of EWS/FLI is not strictly dependent upon DNA-binding activity. Oncogene 1999, 18:5592-5597.
29. Ohno T., Rao V.N., Reddy E.S. EWS/Fli-1 chimeric protein is a transcriptional activator. Cancer Res. 1993, 53:5859-5863.
30. Lessnick S.L., Braun B.S., Denny C.T., May W.A. Multiple domains mediate transformation by the Ewing's sarcoma EWS/FLI-1 fusion gene. Oncogene 1995, 10:423-431.
31. Rossow K.L., Janknecht R. The Ewing's sarcoma gene product functions as a transcriptional activator. Cancer Res. 2001, 61:2690-2695.
32. Araya N., Hirota K., Shimamoto Y., Miyagishi M., Yoshida E., Ishida J., Kaneko S., Kaneko M., Nakajima T., Fukamizu A. Cooperative interaction of EWS with CREB-binding protein selectively activates hepatocyte nuclear factor 4-mediated transcription. J. Biol. Chem. 2003, 278:5427-5432.
33. Rorie C.J., Weissman B.E. The Ews/Fli-1 fusion gene changes the status of p53 in neuroblastoma tumor cell lines. Cancer Res. 2004, 64:7288-7295.
34. Chandar N., Billig B., McMaster J., Novak J. Inactivation of p53 gene in human and murine osteosarcoma cells. Brit. J. Cancer 1992, 65:208-214.
35. Wu X., Bayle J.H., Olson D., Levine A.J. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 1993, 7:1126-1132.
36. Ringshausen I., O'Shea C.C., Finch A.J., Swigart L.B., Evan G.I. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 2006, 10:501-514.
37. Leng R.P., Lin Y., Ma W., Wu H., Lemmers B., Chung S., Parant J.M., Lozano G., Hakem R., Benchimol S. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 2003, 112:779-791.
38. Dornan D., Wertz I., Shimizu H., Arnott D., Frantz G.D., Dowd P., O'Rourke K., Koeppen H., Dixit V.M. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 2004, 429:86-92.
39. Chen D., Kon N., Li M., Zhang W., Qin J., Gu W. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell 2005, 121:1071-1083.
40. Insinga A., Monestiroli S., Ronzoni S., Carbone R., Pearson M., Pruneri G., Viale G., Appella E., Pelicci P., Minucci S. Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. EMBO J. 2004, 23:1144-1154.
41. D'Arcy P., Maruwge W., Ryan B.A., Brodin B. The oncoprotein SS18-SSX1 promotes p53 ubiquitination and degradation by enhancing HDM2 stability. Mol. Cancer Res. 2008, 6:127-138.